Pardes Biosciences, Inc. (PRDS) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
2173 SALK AVENUE CARLSBAD, CA 92008 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 6/30/2023 MRQ | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments, including: | 197,300,000 | 268,678,000 | |||
| Cash and cash equivalents | 59,284,000 | 268,678,000 | |||
| Short-term investments | 138,056,000 | ||||
| Other undisclosed cash, cash equivalents, and short-term investments | (40,000) | ||||
| Prepaid expense | 3,062,000 | 6,581,000 | |||
| Debt securities, available-for-sale, accrued interest, after allowance for credit loss | 300,000 | ||||
| Other undisclosed current assets | (260,000) | ||||
| Total current assets: | 200,402,000 | 275,259,000 | |||
| Noncurrent Assets | |||||
| Other noncurrent assets | 219,000 | ||||
| Total noncurrent assets: | 219,000 | ||||
| TOTAL ASSETS: | 200,621,000 | 275,259,000 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 20,425,000 | 8,965,000 | |||
| Accounts payable | 4,929,000 | 2,385,000 | |||
| Accrued liabilities | 15,496,000 | 6,580,000 | |||
| Total current liabilities: | 20,425,000 | 8,965,000 | |||
| Noncurrent Liabilities | |||||
| Total liabilities: | 20,425,000 | 8,965,000 | |||
| Equity | |||||
| Equity, attributable to parent | 180,196,000 | 266,294,000 | |||
| Common stock | 6,000 | 6,000 | |||
| Additional paid in capital | 328,372,000 | 317,812,000 | |||
| Accumulated other comprehensive income (loss) | (24,000) | ||||
| Accumulated deficit | (148,158,000) | (51,524,000) | |||
| Total equity: | 180,196,000 | 266,294,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 200,621,000 | 275,259,000 | |||
Income Statement (P&L) (USD)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|
| Operating expenses | (99,817,000) | (38,488,000) | ||
| Other undisclosed operating income | 76,976,000 | |||
| Operating income (loss): | (99,817,000) | 38,488,000 | ||
| Income (loss) from continuing operations: | (99,817,000) | 38,488,000 | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | 38,488,000 | ||
| Net income (loss): | (99,817,000) | 38,488,000 | ||
| Other undisclosed net income (loss) attributable to parent | 3,183,000 | (77,006,000) | ||
| Net loss available to common stockholders, diluted: | (96,634,000) | (38,518,000) | ||
Comprehensive Income (USD)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|
| Net income (loss): | (99,817,000) | 38,488,000 | ||
| Other comprehensive income (loss) | (24,000) | |||
| Other undisclosed comprehensive loss | ||||
| Comprehensive income (loss): | (99,841,000) | 38,488,000 | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 3,183,000 | |||
| Comprehensive income (loss), net of tax, attributable to parent: | (96,658,000) | 38,488,000 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.